Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.34 |
| ▸ | HPGD | P15428 | 7/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16273737 | 0.93 | HPGD (0.36) | KDM4EHPGDHTTMRGPRX4ALDH1A1 | |
| SCHEMBL16273681 | 0.91 | MRGPRX4 (0.35) | KDM4EHPGDSMN1; SMN2HTTPTGER1 | |
| SCHEMBL16273656 | 0.91 | KDM4E (0.33) | KDM4EHPGDSMN1; SMN2HTTPTGER1 | |
| SCHEMBL17600071 | 0.91 | PTGER1 (0.35) | KDM4EHPGDSMN1; SMN2HTTPTGER1 | |
| SCHEMBL16273640 | 0.91 | MRGPRX4 (0.34) | KDM4EHPGDSMN1; SMN2HTTPTGER1 | |
| SCHEMBL16273664 | 0.90 | HPGD (0.36) | KDM4EHPGDMRGPRX4ALDH1A1KMT2A | |
| SCHEMBL17600113 | 0.90 | KDM4E (0.34) | KDM4EHPGDSMN1; SMN2HTTPTGER1 | |
| SCHEMBL16911090 | 0.90 | KDM4E (0.31) | KDM4EHPGDSMN1; SMN2HTTMRGPRX4 | |
| SCHEMBL16273642 | 0.89 | HPGD (0.35) | KDM4EHPGDSMN1; SMN2HTTMRGPRX4 | |
| SCHEMBL16273620 | 0.89 | CXCR2 (0.36) | KDM4EHPGDSMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006440-B1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL CO (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-3006440-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006440-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | KDM4E 2537/4885HPGD 4259/4885SMN1; SMN2 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.